Patents Assigned to DeuteRx, LLC
  • Patent number: 10555946
    Abstract: The invention provides 3-deuterium-enriched 3-(6-, 7-, or 8-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: February 11, 2020
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • Patent number: 10202316
    Abstract: The invention provides 3-deuterium-enriched 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same, such as in the treatment of cancer, an immune-related disease, or an inflammatory disease.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 12, 2019
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • Patent number: 10189858
    Abstract: The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4H)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: January 29, 2019
    Assignee: DeuteRx, LLC
    Inventor: Vincent Jacques
  • Patent number: 10188639
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: January 29, 2019
    Assignee: DeuteRx, LLC
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H. T. van der Ploeg
  • Publication number: 20180118758
    Abstract: The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4H)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Application
    Filed: October 13, 2017
    Publication date: May 3, 2018
    Applicants: DeuteRx, LLC, DeuteRx, LLC
    Inventor: Vincent Jacques
  • Patent number: 9925175
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 27, 2018
    Assignee: DeuteRx, LLC
    Inventor: Anthony W. Czarnik
  • Patent number: 9913845
    Abstract: The invention provides 3-deuterium-enriched 3-(6-, 7-, or 8-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: March 13, 2018
    Assignee: DEUTERX, LLC
    Inventor: Sheila DeWitt
  • Patent number: 9833445
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: December 5, 2017
    Assignee: DEUTERX, LLC
    Inventor: Sheila DeWitt
  • Patent number: 9809603
    Abstract: The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4H)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: November 7, 2017
    Assignee: DEUTERX, LLC
    Inventor: Vincent Jacques
  • Patent number: 9732031
    Abstract: The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 15, 2017
    Assignee: DeuteRx, LLC
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H. T. van der Ploeg
  • Patent number: 9540340
    Abstract: The invention provides 3-deuterium-enriched 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same, such as in the treatment of cancer, an immune-related disease, or an inflammatory disease.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: January 10, 2017
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • Publication number: 20160331737
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Application
    Filed: January 15, 2015
    Publication date: November 17, 2016
    Applicant: DeuteRx, LLC
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • Patent number: 9416117
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 16, 2016
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • Patent number: 9290475
    Abstract: The invention provides 3-deuterium-enriched 3-(6-, 7-, or 8-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 22, 2016
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • Patent number: 9090585
    Abstract: The present application describes 2-(2?,6?-dioxo-3?-deutero-piperidin-3?-yl)isoindoles, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: July 28, 2015
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • Patent number: 8969581
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 3, 2015
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • Publication number: 20140329851
    Abstract: The present application describes deuterium-enriched prasugrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Application
    Filed: February 7, 2014
    Publication date: November 6, 2014
    Applicant: DEUTERX, LLC
    Inventor: Anthony W. Czarnik
  • Publication number: 20140288101
    Abstract: The invention provides 3-deuterium-enriched 3-(6-, 7-, or 8-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: DEUTERX, LLC
    Inventor: Sheila DeWitt
  • Publication number: 20140275180
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: DEUTERX, LLC
    Inventor: Sheila DeWitt
  • Publication number: 20140243377
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: DEUTERX, LLC
    Inventor: Anthony W. Czarnik